-
1.发明申请ANTITUMOR VACCINATION USING ALLOGENEIC TUMOR CELLS EXPRESSING ALPHA (1,3)-GALACTOSYLTRANSFERASE 有权使用表达ALPHA（1,3） - 乳酸脱氢酶的ALLOGENEIC肿瘤细胞的抗肿瘤疫苗公开(公告)号：US20110250233A1
公开(公告)日：2011-10-13
申请号：US12878756
申请日：2010-09-09
CPC分类号： A61K39/395 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α半乳糖基表位导致肿瘤细胞的调理作用增强了抗原呈递细胞对调理肿瘤细胞的摄取，这导致增强的肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
2.发明授权Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase 有权使用表达α（1,3） - 半乳糖转移酶的同种异体肿瘤细胞的抗肿瘤疫苗接种公开(公告)号：US09474801B2
公开(公告)日：2016-10-25
申请号：US13966446
申请日：2013-08-14
IPC分类号： A61K35/00 , A61K39/385 , C12N5/09 , C12N5/22 , A61K39/395 , A01K67/027 , A61K39/00
CPC分类号： A61K39/395 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α半乳糖基表位导致肿瘤细胞的调理作用增强了抗原呈递细胞对调理肿瘤细胞的摄取，这导致增强的肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
3.发明授权Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase 有权使用表达α（1,3） - 半乳糖转移酶的同种异体肿瘤细胞的抗肿瘤疫苗接种公开(公告)号：US08535658B2
公开(公告)日：2013-09-17
申请号：US12878756
申请日：2010-09-09
IPC分类号： A61K48/00 , A61K39/39 , A61K31/70 , A61K39/395
CPC分类号： A61K39/395 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α半乳糖基表位导致肿瘤细胞的调理作用，通过抗原呈递细胞增强调理肿瘤细胞的摄取，导致增强的肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
4.发明授权Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase 有权使用表达α（1,3） - 半乳糖转移酶的同种异体肿瘤细胞的抗肿瘤疫苗接种公开(公告)号：US09474771B2
公开(公告)日：2016-10-25
申请号：US14012172
申请日：2013-08-28
IPC分类号： A61K35/00 , A61K39/385 , C12N5/09 , C12N5/22 , A61K35/13 , A01K67/027 , A61K39/00 , C12N5/10
CPC分类号： A61K35/13 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156 , C12N5/10
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α-半乳糖基表位导致肿瘤细胞的调理作用，增强了抗原呈递细胞对调理肿瘤细胞的摄取，从而导致肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
5.发明授权Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase 有权使用表达α（1,3） - 半乳糖转移酶的同种异体肿瘤细胞的抗肿瘤疫苗接种公开(公告)号：US08551474B2
公开(公告)日：2013-10-08
申请号：US12890178
申请日：2010-09-24
CPC分类号： A61K35/13 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156 , C12N5/10
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α-半乳糖基表位导致肿瘤细胞的调理作用，通过抗原呈递细胞增强调理肿瘤细胞的摄取，导致增强的肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
6.发明申请ANTITUMOR VACCINATION USING ALLOGENEIC TUMOR CELLS EXPRESSING ALPHA (1,3)-GALACTOSYLTRANSFERASE 有权使用表达ALPHA（1,3） - 乳酸脱氢酶的ALLOGENEIC肿瘤细胞的抗肿瘤疫苗公开(公告)号：US20110086067A1
公开(公告)日：2011-04-14
申请号：US12890178
申请日：2010-09-24
CPC分类号： A61K35/13 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156 , C12N5/10
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α-半乳糖基表位导致肿瘤细胞的调理作用，增强了抗原呈递细胞对调理肿瘤细胞的摄取，从而导致肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
7.发明申请ANTITUMOR VACCINATION USING ALLOGENEIC TUMOR CELLS EXPRESSING ALPHA (1,3)-GALACTOSYLTRANSFERASE 有权使用表达ALPHA（1,3） - 乳酸脱氢酶的ALLOGENEIC肿瘤细胞的抗肿瘤疫苗公开(公告)号：US20140072597A1
公开(公告)日：2014-03-13
申请号：US14012172
申请日：2013-08-28
IPC分类号： A61K39/00
CPC分类号： A61K35/13 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156 , C12N5/10
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α-半乳糖基表位导致肿瘤细胞的调理作用，通过抗原呈递细胞增强调理肿瘤细胞的摄取，导致增强的肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
8.发明申请ANTITUMOR VACCINATION USING ALLOGENEIC TUMOR CELLS EXPRESSING ALPHA (1,3)-GALACTOSYLTRANSFERASE 有权使用表达ALPHA（1,3） - 乳酸脱氢酶的ALLOGENEIC肿瘤细胞的抗肿瘤疫苗公开(公告)号：US20140037692A1
公开(公告)日：2014-02-06
申请号：US13966446
申请日：2013-08-14
IPC分类号： A61K39/00
CPC分类号： A61K39/395 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α半乳糖基表位导致肿瘤细胞的调理作用，通过抗原呈递细胞增强调理肿瘤细胞的摄取，导致增强的肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.03 秒)
